NCT06138639 - A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

May 6, 2027

Study Completion Date

May 6, 2031

Conditions

Duchenne Muscular Dystrophy

Interventions

GENETIC

SGT-003

Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)

Trial Locations (12)

23510

RECRUITING

Children's Hospital of the King's Daughters, Norfolk

30329

RECRUITING

Rare Disease Research, Atlanta

43215

RECRUITING

Nationwide Children's Hospital, Columbus

63110

RECRUITING

Washington University in St. Louis, St Louis

72202

RECRUITING

Arkansas Children's Hospital, Little Rock

90095

RECRUITING

University of California, Los Angeles Medical Center, Los Angeles

92037

RECRUITING

University of California, San Diego

95817

RECRUITING

University of California, Davis, Sacramento

60611-2605

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

M5G 0A4

RECRUITING

The Hospital for Sick Children, Toronto

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome

WC1N 3JH

RECRUITING

Great Ormond Street Hospital, London

All Listed Sponsors

lead

Solid Biosciences Inc.

INDUSTRY